Belite Bio, Inc (BLTE) Earnings Call Transcripts
Belite Bio, Inc's Latest Earnings Call - June 8, 2026
In the second quarter of 2026, Belite Bio, Inc. (BLTE:US) reported significant progress in its clinical development, particularly with its lead asset, Tinlaribant (LBS008), which is in the process of a rolling NDA submission for Stargardt disease. The company highlighted a statistically significant efficacy signal from the DRAGON trial, with a p-value of 0.003 for the primary endpoint of lesion growth. Management maintained a strong outlook for the drug's approval, supported by robust safety data and a clear regulatory pathway, indicating a potential market launch in the near future. Revenue and earnings specifics were not disclosed in the call, but management emphasized their financial readiness with $800 million in cash to support commercialization efforts.
Reported metrics
| Metric | Value |
|---|---|
| Cash Position | $800 million (positive) |
| Efficacy p-value | 0.003 (positive) |
| Serious Adverse Events (SAEs) | 6 (positive) |
| Projected Patient Population | 49,000 - 57,000 (positive) |
| Commercialization Budget | $300 million (positive) |
| Projected Burn Rate | $450 million - $500 million (neutral) |
Guidance from management
Management expressed confidence in the regulatory approval process for Tinlaribant, with plans for a U.S. launch contingent on successful NDA submission. They are also preparing for potential post-marketing commitments through the DRAGON 2 trial.
What management said
Sure, sure. SP1 So well, we do see that launching for Saga in the U.S. is something that we can do given this rare disease. And we do believe that we have a team that experience about IRD -- at the same time, we do sit on $800 million cash. So our budget for commercialized for this in the U.S., probably somewhere about $300 million. with our existing pipeline, probably cost of $150 million for the next 3 years. So in...
Well, yes, so with the rare pediatric is destination, if the drug is approved, we should be qualified for PRV. The calculation that I just shared does not include that potential additional $100 million to $200 million proceeds from PRB.
What analysts pressed on
Analysts raised questions about the competitive landscape and the potential for other therapies to enter the market. There were concerns regarding the timeline for commercialization and the ability to effectively educate patients on genetic testing prior to the drug's launch.
Main topics on the call
- Regulatory Progress — Belite Bio initiated a rolling NDA submission for Tinlaribant, with management expressing confidence based on strong data from the DRAGON trial. Dr. Scholl stated, "we should be in a very strong position with our market ...
- Efficacy Data from DRAGON Trial — The DRAGON trial demonstrated a significant reduction in lesion growth, with a treatment effect showing a progression rate of 0.38 square millimeters per year compared to 0.59 square millimeters per year in the placebo g...
- Safety Profile — Management reported a favorable safety profile for Tinlaribant, with only 6 serious adverse events (SAEs) noted in 104 subjects over two years, and none related to the treatment. This reinforces the drug's tolerability, ...
- Market Opportunity and Patient Population — Management estimates a potential patient population of 49,000 to 57,000 in the U.S. for Stargardt disease, indicating a significant market opportunity. They emphasized the importance of genetic testing for patient identi...
Read the full Belite Bio, Inc transcript (June 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Belite Bio, Inc
Belite Bio, Inc (BLTE) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 23 calls on record spanning August 9, 2023 to June 8, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 23 Belite Bio, Inc earnings call transcripts on record, spanning August 9, 2023 to June 8, 2026. Based on this history, Belite Bio, Inc reports quarterly. The most recent call on file is dated June 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- BLTE
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 23
- First call
- August 9, 2023
- Most recent
- June 8, 2026
- Reporting cadence
- quarterly